Reiner, C.M.; Schneider, M.A.; Weilert, H.; Welcker, K.; Hoedtke, J.; Mahnken, A.H.; Stang, A.; Brüning, R.
Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience. Cancers 2025, 17, 3834.
https://doi.org/10.3390/cancers17233834
AMA Style
Reiner CM, Schneider MA, Weilert H, Welcker K, Hoedtke J, Mahnken AH, Stang A, Brüning R.
Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience. Cancers. 2025; 17(23):3834.
https://doi.org/10.3390/cancers17233834
Chicago/Turabian Style
Reiner, Carolin M., Martin A. Schneider, Hauke Weilert, Klara Welcker, Jochen Hoedtke, Andreas H. Mahnken, Axel Stang, and Roland Brüning.
2025. "Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience" Cancers 17, no. 23: 3834.
https://doi.org/10.3390/cancers17233834
APA Style
Reiner, C. M., Schneider, M. A., Weilert, H., Welcker, K., Hoedtke, J., Mahnken, A. H., Stang, A., & Brüning, R.
(2025). Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience. Cancers, 17(23), 3834.
https://doi.org/10.3390/cancers17233834
